Zuberbier T. et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticarial: the 2013 revision and update. Allergy, 2014, 69: 868-887.

Vestergaard C, Deleuran M. Chronic spontaneous urticarial: latest developments in aetiology, diagnosis and therapy. Therapeutic Advances in Chronic Disease, 2015, 6(6): 304- 313

Tharp MD. The clinical efficacy of antihistamines in the skin. Allergy, 2000, 55: 11-16.

Kaplan AP. Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol, 2004, 114(3): 465-474.

Аравийская Е.Р., Соколовский Е.В., Галлямова Ю.Э. Федеральные клинические рекомендации по ведению больных крапивницей. М., 2015.

Скрипкин Ю.К., Бутов Ю.С., Иванов О.Л. Дерматовенерология – национальное руководство. М.: ГЭОТАР-Медиа, 2013: 694-702.

Колхир П.В. Причины хронической крапивницы. Лечащий врач, 2012, 10: 80.

Bernstein J.A. Chronic Urticaria: An Evolving Story. IMAJ, 2005, 7: 774–777.

Humphreys F, Hunter JA. The characteristics of urticaria in 390 patients. Br J Dermatol, 1998, 138(4): 635-8.

Ortonne J-P. Urticaria and its subtypes: The role of second-generation antihistamines. Eur J Intern Med, 2012, 23: 26-30.

O’Donnell BF, Lawlor F, Simpson J et al. The impact of chronic urticaria on quality of life. Br J Dermatol, 1997, 136: 197-201.

Grob JJ, Gaudy-Marqueste C. Urticaria and quality of life. Clin Rev Allergy Immunol, 2006, 30(1): 47-51.

Grob J-J, Revuz J, Ortonne J-P, et al. Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life. Br J Dermatol, 2005, 152: 289-295.

Perkowska J, Kruszewski J, Gutkowski P et al. Occurrence of sleep-related breathing disorders in patients with chronic urticaria at its asymptomatic or oligosymptomatic stages. Adv Dermatol Allergol, 2016, XXXIII(1): 63-67.

Zuberbier T, Asero R, Bindslev-Jensen C et al. EAACI/GA2LEN/EDF/WAO guideline: management of urticarial. Allergy, 2009, 64: 1427-1443.

Zuberbier T, Aberer W, Asero R et al. The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy, 2014, 69: 868-887.

Bernstein JA, Lang DM, Khan DA. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol, 2014, 133: 1270-1277.

Jáuregui I., Ferrer M., Montoro J et al. Antihista mines in the treatment of chronic urticaria. J Investig Allergol Clin Immunol, 2007, 17(Suppl.2): 41-52.

Simons FE, Silver NA, Gu X, Simons KJ. Clinical pharmacology of H1- antihistamines in the skin. J Allergy Clin Immunol, 2002, 110: 777-783.

Holgate ST, Canonica GW, Simons FER et al. Consensus Group on New-Generation Antihistamines (CONGA): present status and recommendations. Clin Exp Allergy, 2003, 33: 1305-1324.

Hayashi S, Hashimoto S. Anti-inflammatory actions of new antihistamines. Clin Exp Allergy, 1999, 29: 1593-1596.

Walsh GM. The clinical relevance of the antiinflammatory properties of antihistamines. Allergy, 2000, 55(suppl.60): 53-61.

Leurs R, Church MK, Taglialatela M. H1-antihista mines: inverse agonism, anti- inflammatory actions and cardiac effects. Clin Exp Allergy, 2002, 32: 489-498.

Wolthers OD. Bilastine: A New Nonsedating Oral H1 Antihistamine for treatment of allergic rhinoconjunctivitis and urticaria. BioMed Research International, 2013, Article ID 626837, 6 p.

Bakker RA, Schoonus SBJ, Smit MJ et al. Histamine H1-receptor activation of nuclear factor-kB: roles for Gβγ- and Gα(q/11)-subunits in constitutive and agonist-mediated signaling. Mol Pharmacol, 2001, 60: 1133-1142.

Agrawal DK. Anti-inflammatory properties of desloratadine. Clin Exp Allergy, 2004, 34: 1342-1348.

Picado C. Rupatadine: pharmacological profile and its use in the treatment of allergic disorders. Expert Opin. Pharmacother., 2006, 7(14): 1989-2001.

Wang XY, Lim-Jurado M, Prepageran N et al. Treatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastine. Therapeutics and Clinical Risk Management, 2016, 12: 585-597.

Khan DA. Chronic urticaria: diagnosis and management. Allergy Asthma Proc, 2008, 29(5): 439-446.

Liu H, Farley JM. Effects of first and second generation antihistamines on muscarinic induced mucus gland cell ion transport. BMC Pharmacology, 2005, 5: 1-10.

Gillard M, Christophe B, Wels B et al. H1 antagonists: receptor affinity versus selectivity. Inflamm. Res, 2003, 52(Suppl.1): S49-S50.

Monroe E. Review of H1 antihistamines in the treatment of chronic idiopathic urticaria. Cutis, 2005, 76: 118-126.

Kavosh ER, Khan DA. Second-generation H1-antihistamines in chronic urticaria an evidence-based review. Am J Clin Dermatol, 2011, 12(6): 361-376.

Скрипкин Ю.К., Дворников А.С., Круглова Л.С., Скрипкина П.А. Современный взгляд на патогенетическую терапию атопического дерматита. Вестник дерматологии и венерологии, 2006, 4: 36-39.

Simons FERS, Simons KJ. H1 Antihistamines: current status and future directions. WAO Journal, 2008: 145-155.

Cuvillo A, Mullol J, Bartra J et al. Comparative pharmacology of the H1 antihistamines. J Investig Allergol Clin Immunol, 2006, 16(Suppl 1): 3-12.

Jáuregui I, Ortiz de Frutos FJ, Ferrer M. Assess ment of severity and quality of life in chronic urticaria. J Investig Allergol Clin Immunol, 2014, 24(2): 80-86.

Baiardini I, Pasquali M, Braido F. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL). Allergy, 2005, 60(8): 1073-1078.

Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol, 1994, 19: 210-216.

Некрасова Е.Е., Разваляева А.В., Малюжинская Н.В. Разработка русской версии опросника CU-QoL для изучения качества жизни у больных с хронической крапивницей. Саратовский научно-медицинский журнал, 2010, 6(3): 566-569.

Grob J-J, Lachapelle J-M. Non-sedating antihistamines in the treatment of chronic idiopathic urticaria using patient-reported outcomes. Current Medical Research and Opinion, 2008, 24(8): 2423-2428.

Kapp А, Pichler WJ. Pharmacology and therapeutics levocetirizine is an effective treatment in patients suffering from chronic idiopathic urticaria: a randomized, double- blind, placebo-controlled, parallel, multicenter study. Int J Dermatol, 2006, 45: 469-474.

Spector SL, Shikiar R, Harding G et al. The effect of fexofenadine hydrochloride on productivity and quality of life in patients with chronic idiopathic urticaria. Cutis, 2007, 79(2): 157-162.

Zuberbier T, Oanta A, Bogacka E et al. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: а multicentre, double-blind, randomized, placebo-controlled study. Allergy, 2010, 65(4): 516-528.

Juhlin L. A comparison of the pharmacodynamics of H1-receptor antagonists as assessed by the induced wheal-and-flare model. Allergy, 1995, 50: 24-30.

Kruszewski J, Kłos K, Sułek K. Inhibition of histamine-induced wheel after a recommended single dose administration of 10 mg cetirizine, 5 mg desloratadine, 120 and 180 mg fexofenadine, 5 mg levocetirizine and 10 mg loratadine–a randomized, double- blind, placebo controlled trial. Pol Merkur Lekarski, 2006, 21(125): 443-448.

Kłos K, Kruszewski J, Kruszewski R, Sułek K. The effect of 5-days of cetirizine, desloratadine, fexofenadine 120 and 180 mg, levocetirizine, loratadine treatment on the histamine-induced skin reaction and skin blood flow–a randomized, double-blind, placebo controlled trial. Pol Merkur Lekarski, 2006, 21(125): 449-453.

Simons FE, McMillan JL, Simons KJ. A doubleblind, single-dose, crossover comparison of cetirizine, terfenadine, loratadine, astemizole, and chlorpheniramine versus placebo: suppressive effects on histamine-induced wheals and flares during 24 hours in normal subjects. J Allergy Clin Immunol, 1990, 86: 540-7.

Rosenzwey P, Caplain H, Chofour S et al. Comparative wheal and flare study of mizolastine vs terfenadine,cetirizine, loratadine and placebo in healthy volunteers. Br J Clin Pharmacol, 1995, 40: 459-465.

Grant JA, Danielson L, Rihoux JP, DeVos C. A double-blind, single-dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo: suppression of histamine-induced wheal and flare response for 24 h in healthy male subjects. Allergy,. 1999, 54: 700-707.

Grant JA, Riethuisen JM, Moulaert B, DeVos C. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-andflare response during 24 hours in healthy male subjects. Ann Allergy Asthma Immunol, 2002, 88(2): 190-197.

Popov TA, Dumitrascu D, Bachvarova A et al. A comparison of levocetirizine and desloratadine in the histamine-induced wheal and flare response in human skin in vivo. Inflamm Res, 2006, 55(6): 241-244.

Roongapinun S, Wajajamreon S, Fooanant S. Comparative efficacy of wheal-and-flare suppression among various non-sedating antihistamines and the pharmacologic insights to their efficacy. J Med Assoc Thai, 2004, 87(5): 551-6.

Meltzer EO, Gillman SA. Efficacy of fexofenadine versus desloratadine in suppressing histamineinduced wheal and flare. Allergy Asthma Proc, 2007, 28: 67-73.

Kaliner MA, White MV, Economides A et al. Relative potency of fexofenadine HCl 180 mg, loratadine 10 mg, and placebo using a skin test model of wheal-and-flare suppression. Ann Allergy Asthma Immunol, 2003, 90: 629-634.

Frossard N, Strolin-Benedetti M, Purohit A, Pauli G. Inhibition of allergen-induced wheal and flare reactions by levocetirizine and desloratadine. Br J Clin Pharmacol, 2007, 65(2): 172-179.

Fadel R, David B, Heprin-Richard N et al. In vivo effects of cetirizine on cutaneous reactivity and eosinophil migration induced by platelet activating factor in man. J Allergy Clin Immunol, 1990, 86: 314-320.

Charlesworth EN, Massey WA, Kagey-Sobotka A et al. Effect of H1 receptor blockade on the early and late response to cutaneous allergen challenge. J Pharmacol Exp Ther, 1992, 262: 964-970.

Walsh GM. The anti-inflammatory effects of levocetirizine – are they clinically relevant or just an interesting additional effect? Allergy, Asthma & Clinical Immunology, 2009, 5: 14.

Caproni M, Volpi W, Giomi B et al. Cellular adhesion molecules in chronic urticaria: modulation of serum levels occurs during levocetirizine treatment. Br J Dermatol, 2006, 155: 1270-1274.

Simons FER, Silver NA, Gu X, Simons KJ. Skin concentrations of H1-receptor antagonists. J Allergy Clin Immunol. 2001, 107: 526-530.

Sharma M, Bennett C, Cohen SN, Carter B. H1-anti -hista mines for chronic spontaneous urticaria. Cochrane Database of Systematic Reviews, 2014, Issue 11.

Kozel MM, Mekkes JR, Bossuyt PM, Bos JD. Natural course of physical and chronic urticaria and angioedema in 220 patients. J Am Acad Dermatol, 2001, 45(3): 387-391.

Kameyoshi Y, Tanaka T, Mihara S et al. Increasing the dose of cetirizine may lead to better control of chronic idiopathic urticaria: An open study of 21 patients. Br J Dermatol., 2007, 157: 803-804.

Asero R. Chronic unremitting urticaria: Is the use of antihistamines above the licensed dose effective? A preliminary study of cetirizine at licensed and abovelicensed doses. Clin Exp Dermatol, 2007, 32: 34-38.

Staevska M, Popov TA, Kralimarkova T et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol, 2010, 125: 676-682.